Ruzinurad
Appearance
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H12BrNO2S |
Molar mass | 338.22 g·mol−1 |
3D model (JSmol) | |
| |
|
Ruzinurad (SHR4640) is a selective urate transporter 1 (URAT1) inhibitor in development for hyperuricaemia and gout. It is developed by Jiangsu Hengrui.[1][2][3][4][5][6]
References
[edit]- ^ Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian; Wang, Zhongming; Long, Wubin; Li, Zhijun; Jiang, Gengru; Li, Xiaomei; Bi, Liqi; Jiang, Lindi; Wu, Jian; Guo, Lian; Cai, Xiaoyan; Lu, Xin; Chen, Qinkai; Chen, Hong; Peng, Ai; Zuo, Xiaoxia; Ning, Rui; Zhang, Zhe; Tai, Yanfei; Zhang, Tao; Bao, Chunde (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology. 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. ISSN 1462-0332. PMID 33693494.
- ^ Wang, Chenjing; Yu, Qing; Jiang, Xin; Deng, Yujie; Sun, Feifei; Li, Xin; Tao, Ye; Lin, Pingping; Ma, Yaping; Zhu, Yuxian; Li, Chengqian; Cao, Yu (February 2023). "A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia". The Journal of Clinical Pharmacology. 63 (2): 239–249. doi:10.1002/jcph.2159. PMID 36131360. S2CID 252437511.
- ^ Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo; Wang, Xiaoxia; Jiang, Zhenyu; Li, Detian; Wang, Zhongming; Long, Wubin; Li, Zhijun; Jiang, Gengru; Li, Xiaomei; Bi, Liqi; Jiang, Lindi; Wu, Jian; Guo, Lian; Cai, Xiaoyan; Lu, Xin; Chen, Qinkai; Chen, Hong; Peng, Ai; Zuo, Xiaoxia; Ning, Rui; Zhang, Zhe; Tai, Yanfei; Zhang, Tao; Bao, Chunde (3 November 2021). "Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study". Rheumatology. 60 (11): 5089–5097. doi:10.1093/rheumatology/keab198. PMID 33693494.
- ^ Liang, Beibei; Wang, Jin; Bai, Nan; Zhuo, Jiaju; Wang, Rui; Lin, Hongda; Cai, Yun (April 2023). "Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of SHR4640, a Selective Urate Transporter 1 Inhibitor, in Healthy Chinese Male Volunteers". Clinical Pharmacology in Drug Development. 12 (4): 392–396. doi:10.1002/cpdd.1191. ISSN 2160-7648. PMID 36317751. S2CID 253245027.
- ^ "A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout". www.clinicaltrials.gov. Retrieved 11 November 2023.
- ^ Tang, Honghu; Cui, Beibei; Chen, Yiyu; Chen, Lin; Wang, Zhihong; Zhang, Ning; Yang, Yanlan; Wang, Xiaodong; Xie, Xiangliang; Sun, Lingyun; Dang, Wantai; Wang, Xianyang; Li, Runzi; Zou, Jianjun; Zhao, Yi; Liu, Yi (January 2022). "Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study". Therapeutic Advances in Musculoskeletal Disease. 14: 1759720X2110673. doi:10.1177/1759720X211067304. ISSN 1759-720X. PMC 8808016. PMID 35126684.